Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia

References

• Avalle L, Camporeale A, Camperi A, Poli V. 2017. STAT3 in cancer: a double edged sword. Cytokine. 98:42–50.
   PubMed Web of Science ®Google Scholar
• Beider K, Darash-Yahana M, Blaier O, Koren-Michowitz M, Abraham M, Wald H, Wald O, Galun E, Eizenberg O, Peled A, et al. 2014. Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo. Mol Cancer Ther. 13(5):1155–1169.
   PubMed Web of Science ®Google Scholar
• Ćojbašić I, Mačukanović-Golubović L, Mihailović D, Vučić M, Ćojbašić Ž. 2017. The significance of angiogenesis for predicting optimal therapeutic response in chronic myeloid leukaemia patients. Pol J Pathol. 68(3):241–251.
   PubMed Web of Science ®Google Scholar
• Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O'Brien S, Garcia-Manero G, Giles F, Breeden M, Reeves N, et al. 2007. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 110(12):4005–4011.
   PubMed Web of Science ®Google Scholar
• Eiring AM, Page BDG, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, et al. 2017. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia. 31(5):1253–1254.
   PubMed Web of Science ®Google Scholar
• El Fakih R, Chaudhri N, Alfraih F, Rausch CR, Naqvi K, Jabbour E. 2020. Complexity of chronic-phase CML management after failing a second-generation TKI. Leuk Lymphoma. 61(4):776–787.
   PubMed Web of Science ®Google Scholar
• Ge Y, Cheng R, Zhou Y, Shen J, Peng L, Xu X, Dai Q, Liu P, Wang H, Ma X, et al. 2012. Cryptotanshinone induces cell cycle arrest and apoptosis of multidrug resistant human chronic myeloid leukemia cells by inhibiting the activity of eukaryotic initiation factor 4E. Mol Cell Biochem. 368(1–2):17–25.
   PubMed Web of Science ®Google Scholar
• Ge Y, Yang B, Xu X, Dai Q, Chen Z, Cheng R. 2015a. Cryptotanshinone acts synergistically with imatinib to induce apoptosis of human chronic myeloid leukemia cells. Leuk Lymphoma. 56(3):730–738.
   PubMed Web of Science ®Google Scholar
• Ge Y, Yang B, Chen Z, Cheng R. 2015b. Cryptotanshinone suppresses the proliferation and induces the apoptosis of pancreatic cancer cells via the STAT3 signaling pathway. Mol Med Rep. 12(5):7782–7788.
   PubMed Web of Science ®Google Scholar
• Gebreyohannes YK, Wozniak A, Zhai ME, Wellens J, Cornillie J, Vanleeuw U, Evans E, Gardino AK, Lengauer C, Debiec-Rychter M, et al. 2019. Robust activity of avapritinib, potent and highly selective inhibitor of mutated KIT, in patient-derived xenograft models of gastrointestinal stromal tumors. Clin Cancer Res. 25(2):609–618.
   PubMed Web of Science ®Google Scholar
• Gleixner KV, Schneeweiss M, Eisenwort G, Berger D, Herrmann H, Blatt K, Greiner G, Byrgazov K, Hoermann G, Konopleva M, et al. 2017. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia. Haematologica. 102(9):1519–1529.
   PubMed Web of Science ®Google Scholar
• Guzińska-Ustymowicz K, Pryczynicz A, Kemona A, Czyzewska J. 2009. Correlation between proliferation markers: PCNA, Ki-67, MCM-2 and antiapoptotic protein Bcl-2 in colorectal cancer. Anticancer Res. 29(8):3049–3052.
   PubMed Web of Science ®Google Scholar
• Hao W, Zhang X, Zhao W, Zhu H, Liu ZY, Lu J, Chen X. 2016. Cryptotanshinone induces pro-death autophagy through JNK signaling mediated by reactive oxygen species generation in lung cancer cells. Anticancer Agents Med Chem. 16(5):593–600.
   PubMed Web of Science ®Google Scholar
• Jain N, O'Brien S. 2013. The frontline treatment of chronic myeloid leukemia in the chronic phase: current clinical decisions and future prospects for treatment. Expert Rev Hematol. 6(5):575–586.
   PubMed Web of Science ®Google Scholar
• Juríková M, Danihel Ľ, Polák Š, Varga I. 2016. Ki67, PCNA, and MCM proteins: markers of proliferation in the diagnosis of breast cancer. Acta Histochem. 118(5):544–552.
   PubMed Web of Science ®Google Scholar
• Kuepper MK, Bütow M, Herrmann O, Ziemons J, Chatain N, Maurer A, Kirschner M, Maié T, Costa IG, Eschweiler J, et al. 2019. Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling. Leukemia. 33(8):1964–1977.
   PubMed Web of Science ®Google Scholar
• Larsson O, Li S, Issaenko OA, Avdulov S, Peterson M, Smith K, Bitterman PB, Polunovsky VA. 2007. Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors. Cancer Res. 67(14):6814–6824.
   PubMed Web of Science ®Google Scholar
• Lei H, Jin J, Liu M, Li X, Luo H, Yang L, Xu H, Wu Y. 2018. Chk1 inhibitors overcome imatinib resistance in chronic myeloid leukemia cells. Leuk Res. 64:17–23.
   PubMed Web of Science ®Google Scholar
• Li X, Miao H, Zhang Y, Li W, Li Z, Zhou Y, Zhao L, Guo Q. 2015. Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing STAT3 pathway. Arch Toxicol. 89(1):121–136.
   PubMed Web of Science ®Google Scholar
• Lim S, Saw TY, Zhang M, Janes MR, Nacro K, Hill J, Lim AQ, Chang CT, Fruman DA, Rizzieri DA, et al. 2013. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function. Proc Natl Acad Sci USA. 110(25):E2298–2307.
   PubMed Web of Science ®Google Scholar
• Lin Y, Li D, Liang Q, Liu S, Zuo X, Li L, Sun X, Li W, Guo M, Huang Z. 2015. miR-638 regulates differentiation and proliferation in leukemic cells by targeting cyclin-dependent kinase 2. J Biol Chem. 290(3):1818–1828.
   PubMed Web of Science ®Google Scholar
• Liu Z, Li Y, Lv C, Wang L, Song H. 2016. Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway. Biochem Biophys Res Commun. 478(2):893–899.
   PubMed Web of Science ®Google Scholar
• Marfe G, Di Stefano C. 2014. Bypass mechanisms of resistance to tyrosine kinase inhibition in chronic myelogenous leukaemia. Curr Drug Discov Technol. 11(2):145–153.
   PubMedGoogle Scholar
• Michallet M, Tulliez T, Corm S, Gardembas M, Huguet F, Oukessou A, Bregman B, Vekhoff A, Ghomari K, Cambier N, et al. 2010. Management of chronic myeloid leukaemia in clinical practice in France: results of the French subset of patients from the UNIC study. Curr Med Res Opin. 26(2):307–317.
   PubMed Web of Science ®Google Scholar
• Peng XX, Tiwari AK, Wu HC, Chen ZS. 2012. Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells. Chin J Cancer. 31(2):110–118.
   PubMed Web of Science ®Google Scholar
• Sacha T, Hochhaus A, Hanfstein B, Müller MC, Rudzki Z, Czopek J, Wolska-Smoleń T, Czekalska S, Salamanchuk Z, Jakóbczyk M, et al. 2003. ABL-kinase domain point mutation as a cause of Imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis. Leuk Res. 27(12):1163–1166.
   PubMed Web of Science ®Google Scholar
• Shi F, Len Y, Gong Y, Shi R, Yang X, Naren D, Yan T. 2015. Ribavirin inhibits the activity of mTOR/eIF4E, ERK/Mnk1/eIF4E signaling pathway and synergizes with tyrosine kinase inhibitor imatinib to impair Bcr-Abl mediated proliferation and apoptosis in Ph + leukemia. PLoS One. 10(8):e0136746.
   PubMed Web of Science ®Google Scholar
• Shin DS, Kim HN, Shin KD, Yoon YJ, Kim SJ, Han DC, Kwon BM. 2009. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res. 69(1):193–202.
   PubMed Web of Science ®Google Scholar
• Stella S, Tirrò E, Conte E, Stagno F, Di Raimondo F, Manzella L, Vigneri P. 2013. Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs. Mol Cancer Ther. 12(6):1085–1098.
   PubMed Web of Science ®Google Scholar
• Thielen N, van der Holt B, Cornelissen JJ, Verhoef GE, Gussinklo T, Biemond BJ, Daenen SM, Deenik W, van Marwijk Kooy R, Petersen E, et al. 2013. Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON). Eur J Cancer. 49(15):3242–3246.
   PubMed Web of Science ®Google Scholar
• Traer E, MacKenzie R, Snead J, Agarwal A, Eiring AM, O'Hare T, Druker BJ, Deininger MW. 2012. Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors. Leukemia. 26(5):1140–1143.
   PubMed Web of Science ®Google Scholar
• Wang D, Yu W, Cao L, Xu C, Tan G, Zhao Z, Huang M, Jin J. 2020. Comparative pharmacokinetics and tissue distribution of cryptotanshinone, tanshinone IIA, dihydrotanshinone I, and tanshinone I after oral administration of pure tanshinones and liposoluble extract of Salvia miltiorrhiza to rats. Biopharm Drug Dispos. 41(1–2):54–63.
   PubMed Web of Science ®Google Scholar
• Wang H, Li Q, Tang S, Li M, Feng A, Qin L, Liu Z, Wang X. 2017. The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells. Hematology. 22(4):208–216.
   PubMed Web of Science ®Google Scholar
• Xu Z, Jiang H, Zhu Y, Wang H, Jiang J, Chen L, Xu W, Hu T, Cho CH. 2017. Cryptotanshinone induces ROS-dependent autophagy in multidrug-resistant colon cancer cells. Chem Biol Interact. 273:48–55.
   PubMed Web of Science ®Google Scholar
• Yang H, Chennamaneni LR, Ho MWT, Ang SH, Tan ESW, Jeyaraj DA, Yeap YS, Liu B, Ong EH, Joy JK, et al. 2018. Optimization of selective mitogen-activated protein kinase interacting kinases 1 and 2 inhibitors for the treatment of blast crisis leukemia. J Med Chem. 61(10):4348–4369.
   PubMed Web of Science ®Google Scholar
• Yang K, Fu LW. 2015. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: a review. Crit Rev Oncol Hematol. 93(3):277–292.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Zhao Y, Li J, Tao L, Shi P, Wei Z, Sheng X, Shen D, Liu Z, Zhou L, et al. 2016. Cryptotanshinone, a novel tumor angiogenesis inhibitor, destabilizes tumor necrosis factor-α mRNA via decreasing nuclear-cytoplasmic translocation of RNA-binding protein HuR. Mol Carcinog. 55(10):1399–1410.
   PubMed Web of Science ®Google Scholar